CAR T-Cell Therapy clinical trials at UC Davis
1 research study open to eligible people
Showing trials for
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
“A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Systemic Lupus Erythematosus”
open to eligible people ages 18-65
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Sacramento, California and other locations
Our lead scientists for CAR T-Cell Therapy research studies include Gaurav Gulati, MD.
Last updated: